Comparative Pharmacology
Head-to-head clinical analysis: PENICILLAMINE versus PENTETATE ZINC TRISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLAMINE versus PENTETATE ZINC TRISODIUM.
PENICILLAMINE vs PENTETATE ZINC TRISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.
Pentetic acid (diethylenetriaminepentaacetic acid, DTPA) forms stable chelates with metal ions, particularly radioactive transuranic elements such as plutonium, americium, and curium. The zinc trisodium salt exchanges zinc for the radioactive metal, forming a stable, soluble complex that is rapidly excreted via the kidneys, thereby reducing radiation exposure.
250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.
1 g intravenous infusion over 1-2 hours once daily for up to 5 days.
None Documented
None Documented
Clinical Note
moderatePenicillamine + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Eltrombopag
"The serum concentration of Eltrombopag can be increased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Iron
Terminal half-life: 1.5–2 hours for penicillamine; after chronic dosing, a slower phase (t1/2 ~40 hours) appears due to tissue binding. Clinical context: Dosing interval typically 6–8 hours; accumulation may occur in renal impairment.
The terminal elimination half-life is approximately 1.5 to 2 hours for the Zn-DTPA complex in patients with normal renal function. In the setting of acute radiation exposure, this rapid clearance allows for early chelation.
Renal: ~80% as unchanged drug and metabolites; fecal: ~20% (via biliary elimination).
Primarily renal elimination of the chelated complex (e.g., Zn-DTPA). In adults, >95% of the administered dose is excreted unchanged in urine within 24 hours, with minor biliary/fecal excretion (<5%).
Category C
Category C
Chelating Agent
Chelating Agent
"Penicillamine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy."